In the traditional orthopedic playbook, the path from "napkin sketch" to "FDA clearance" was a straight line through the surgeon. To develop a new product or procedure, a company simply identified a clinical need, partnered with an influential Key Opinion Leader (KOL) to guide prototypes, and relied on that surgeon’s prestige to drive adoption.
But in today’s value-based healthcare environment, that model is dangerously incomplete. In the "old days," if the KOL liked the handle of a shift, the industry assumed the market would follow. Today, if your R&D team is only listening to the person holding the scalpel, you are likely developing a product that will be "Dead on Arrival" before it ever reaches the sterile field.
The Shift: From the Surgeon to the System
While a surgeon might champion an idea based on clinical precision, they often lack visibility into the full financial picture—reimbursement realities, total cost of ownership, or how a new device impacts OR efficiency. Power has shifted from the individual innovator to the Facility Ecosystem, which requires a "360-degree" development strategy from day one.
To secure lasting adoption, new product development must now solve ...
